Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 20;3(3):528-541.
doi: 10.1002/rth2.12204. eCollection 2019 Jul.

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review

Jacky K Yu  1 , Alfonso Iorio  2   3 , Andrea N Edginton  1 ; WAPPS co‐investigators
Collaborators, Affiliations

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review

Jacky K Yu et al. Res Pract Thromb Haemost. .

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] Res Pract Thromb Haemost. 2019 Sep 16;3(4):771. doi: 10.1002/rth2.12258. eCollection 2019 Oct. Res Pract Thromb Haemost. 2019. PMID: 31624799 Free PMC article.

Abstract

The objective of this scoping review is to summarize the current use of pharmacokinetics for tailoring prophylaxis in hemophilia patients switching between clotting factor products. Patients with hemophilia may require switching of clotting factor concentrates due to a variety of factors, but there have been perceived risks associated with switching, such as inhibitor development or suboptimal protection due to inadequate dosing while titrating treatment. Studies that look at patients switching from one clotting factor concentrate to another are categorized in terms of their primary and/or secondary objectives, notably biosimilarity and comparative pharmacokinetic studies and inhibitor development studies. Research on how best to switch concentrates with respect to dosing regimen are lacking, and currently a trial-and-error approach is used for dosing the new factor concentrate. In the future, studies looking at the predictability of pharmacokinetics (PK) of a new factor concentrate based on individual PK knowledge of the original factor concentrate may offer clinical benefit by providing a safer switching approach and protocol.

Keywords: drug substitution; factor IX; factor VIII; hemophilia A; hemophilia B.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flow diagram of WAPPS data
Figure 2
Figure 2
Study flow diagram of PUBMED search
Figure 3
Figure 3
Example of individual PK parameters after switching
See this image and copyright information in PMC

References

    1. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding, bleeding‐related complications in people with hemophilia A or B. Cochrane Database Syst Rev. 2011:Cd003429. - PubMed
    1. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med. 1994;236:391–9. - PubMed
    1. Oldenburg J. Prophylaxis in bleeding disorders. Thromb Res. 2011;127(suppl 1):S14–7. - PubMed
    1. Berntorp E, Astermark J, Baghaei F, Bergqvist D, Holmstrom M, Ljungberg B, et al. Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health‐technology assessment. Haemophilia. 2012;18:158–65. - PubMed
    1. Fischer K, Collins PW, Ozelo MC, Srivastava A, Young G, Blanchette VS. When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. J Thromb Haemost. 2016;14:1105–9. - PubMed

Publication types